In July 2025, ViiV Healthcare, a subsidiary of GSK, announced an expanded voluntary licensing agreement for long-acting Apretude (cabotegravir). This follows the earlier example of Gilead's licensing deals for Sunlenca (lenacapavir) to improve access in low- and middle-income countries. The manufacturing market for diagnostic tests remains dominated by multinational companies such as Abbott, Roche and Siemens Healthnieers; however there has been notable developments from African companies including SD Biosensor and Codix Bio. In May 2025, Codix Bio, a Nigerian health technology company, signed a sublicensing agreement with the Medicines Patent Pool to develop and manufacture rapid diagnostic tests using technology transferred from SD Biosensor.